EN
Home/Guides/Stopping
Guide 9 of 9 · Stage: Live with it

What happens when you stop a GLP-1 like Ozempic or Mounjaro?

Weight regain, blood sugar, lower doses, the long-term cost in dirhams, and how to stop safely.

The short answer

Most people regain much of the lost weight within a year of stopping a GLP-1 medicine such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro). Blood sugar and blood pressure tend to rise again too. Stopping can still be the right choice. Plan it with your doctor, especially if you have diabetes.

Key facts

Weight after stopping
About two-thirds of the loss came back within a year in the main semaglutide trial1
How fast
About 0.8 kg a month after semaglutide or tirzepatide, on average2
Health markers
Blood pressure, sugar and cholesterol drift back towards where they started1,2
Lower dose instead
Tested for tirzepatide only; kept most, not all, of the loss3
Pregnancy plans
Stop semaglutide at least 2 months before trying, says the Wegovy label4
On this page
  1. What happens to your weight when you stop?
  2. What happens to blood sugar, blood pressure and cholesterol?
  3. Why does the weight come back?
  4. Can you take a lower dose, or taper off?
  5. What helps keep weight off?
  6. What does staying on it cost over years?
  7. When is stopping the right call?
  8. How do you stop safely?
  9. What if you miss doses or can't get supply?
  10. Questions people ask

What happens to your weight when you stop?

In trials, most people regained much of the weight they had lost within a year of stopping. On average, they did not go all the way back to where they started.

The clearest test is a one-year follow-up of the main semaglutide trial (the STEP 1 extension). It followed 327 people for a year after treatment stopped: 228 had been on semaglutide 2.4 mg and the rest on a dummy injection.1

STEP 1 extensionSemaglutide 2.4 mg, then stopped

327 people, followed for a year after treatment ended.1 For someone who started at 90 kg:

74.4 kgafter 68 weeks on semaglutide: 15.6 kg lost (−17.3%)
+10.4 kgcame back in the year after stopping, about two-thirds of the loss (+11.6% of starting weight)
85.0 kga year after stopping: still 5 kg below the start (−5.6%). Dummy-injection group: 89.9 kg

So about two-thirds of the lost weight came back. For a 90 kg person, that means losing about 16 kg, then regaining about 10 kg.1 About half the people (48%) were still at least 5% lighter than at the start.1

Weight change before and after stopping semaglutide (STEP 1)

Semaglutide 2.4 mgDummy injection

Average change from starting weight. Lines join the 3 measured points; the real path between them was curved. Source: STEP 1 extension.1

Two more trials tested this differently. Everyone took the medicine first. Then, at random, some carried on and the rest were switched to a dummy injection without knowing. So the gap between the two groups shows what stopping does:

STEP 4Semaglutide 2.4 mg

Everyone took it for 20 weeks, then half switched to a dummy injection for 48 weeks.5 For someone who started at 90 kg:

80.5 kgat the switch, after 20 weeks: 9.5 kg lost (−10.6%)
85.5 kgswitched to the dummy: 5.0 kg of the 9.5 kg came back (−5.0% vs start)
74.1 kgkept taking it: another 6.4 kg off (−7.9% more)
SURMOUNT-4Tirzepatide, highest dose people could take

Everyone took it for 36 weeks, then half switched to a dummy injection for 52 weeks.6 For someone who started at 90 kg:

71.2 kgat the switch, after 36 weeks: 18.8 kg lost (−20.9%)
81.1 kgswitched to the dummy: 9.9 kg of the 18.8 kg came back (−9.9% vs start)
67.3 kgkept taking it: another 3.9 kg off (−5.5% more)

The kg figures are our arithmetic for one example person starting at 90 kg, using each trial's average percentages; real people varied a lot. In both trials about half the lost weight came back after switching. The trials also report regain of 6.9% (STEP 4) and 14.0% (SURMOUNT-4), but those are measured from the lower weight at the switch, so they look different.5,6

Two 2026 reviews pooled many studies. A BMJ review of 37 studies (9,341 people) found weight came back at about 0.8 kg a month after semaglutide or tirzepatide.2 It projected a return to starting weight in about 1.5 years. That is an estimate: no study of these two drugs followed people for more than a year.2

A second review estimated that 60% of the lost weight returns in the first year. It predicted regain would level off at about 75%, not 100%.7 So the two reviews disagree: one projects a full return to starting weight, the other a partial one.2,7 These are averages. In one tirzepatide analysis, 1 in 6 people regained less than a quarter of what they lost.8

What happens to blood sugar, blood pressure and cholesterol?

They tend to drift back towards where they were before treatment. The more weight comes back, the more they rise.

In STEP 1, blood pressure was back at its starting level a year after stopping. Average blood sugar (HbA1c, a 3-month sugar test) and cholesterol also rose again.1

In the tirzepatide trial above (SURMOUNT-4), people who regained the most saw the biggest rises. Top (systolic) blood pressure went up by 7 to 10 points, depending on how much weight came back.8 People who kept most of the weight off kept some benefits, such as lower blood fats (triglycerides).8

If you have type 2 diabetes, this matters most. In people with diabetes, HbA1c rose by an average of 0.65 points after stopping: for example, from 7.0% to about 7.65%.9 See how to stop safely.

The BMJ review projected that all these heart and sugar markers would be back at their starting levels within about 1.4 years.2

Why does the weight come back?

The medicine was holding your appetite down. When it wears off, hunger returns, and your body also pushes to regain lost weight.

Half of each semaglutide dose is still in the body after about a week. It stays in the blood for about 5 to 7 weeks after the last injection.4 As it goes, the feeling of fullness it gave goes too.

Losing weight by any route changes your hunger hormones. In one study of dieting, these changes and stronger hunger were still there a year later.10 The body acts as if it wants the weight back.

This is why experts now call obesity a long-term (chronic) condition, like high blood pressure. The WHO calls it "a chronic, relapsing disease requiring lifelong care".11 The STEP 1 authors said their results suggest ongoing treatment is needed to keep the benefits.1

Regain is not a personal failure. The BMJ review found weight came back faster after medicines than after diet programmes alone, whatever the amount first lost.2

Can you take a lower dose, or taper off?

One good trial says a lower tirzepatide dose keeps most of the weight off. For semaglutide, and for tapering to zero, the evidence is thin.

One trial (SURMOUNT-MAINTAIN) took 378 US adults who had lost weight on tirzepatide 10 or 15 mg. They were split into 3 groups for a year: full dose, 5 mg, or a dummy injection.3

SURMOUNT-MAINTAINTirzepatide: full dose, 5 mg or dummy injection

378 adults.3 Everyone first lost weight on tirzepatide. Then they were split into three groups for a year: kept the full dose, dropped to a low 5 mg dose, or switched to a dummy injection. For someone who started at 90 kg:

Kept the full dose70.3 kga year later: 19.7 kg below the start (−21.9%)8 in 100 put back half or more of what they had lost
Dropped to 5 mg75.1 kga year later: 14.9 kg below the start (−16.6%)25 in 100 put back half or more of what they had lost
Switched to a dummy injection81.1 kga year later: 8.9 kg below the start (−9.9%)67 in 100 put back half or more of what they had lost

Most people in this trial were white women.3 So results may differ for people from other backgrounds, including South Asian and Arab men and women. Eli Lilly, which makes tirzepatide, paid for it.3 Staying on a medicine also means staying with its side effects. In the semaglutide trial above (STEP 4), 42% of people who continued semaglutide had stomach side effects, vs 26% on a dummy injection.5

For semaglutide, no finished trial has tested a lower maintenance dose or a slow taper. The first randomised taper trial, in China, had not started recruiting as of October 2026.12 In real life, many people already use lower doses. In one Danish GP practice, 40% of people still on semaglutide after a year took 1 mg or less.12

The WHO's 2025 guideline names "maintenance and discontinuation" as areas where long-term data are limited.11 So a taper plan is your doctor's judgement, not a proven method.

The risks, in brief Staying on a GLP-1 long term means living with its risks:
  • Common: feeling sick, vomiting, diarrhoea and constipation, mostly when the dose goes up.
  • Rare but serious: inflammation of the pancreas (pancreatitis) and gallbladder problems.
  • Vomiting or diarrhoea can dry you out (dehydration) and harm the kidneys.
  • The US label rules it out for people with a personal or family history of a rare thyroid cancer (MTC), or with MEN2; tell your doctor if this applies.
  • Not for use in pregnancy.
Read Guide 5: Side effects and risks →

What helps keep weight off?

Keeping up exercise and support with eating and habits help most. Nothing yet fully replaces the medicine.

A Danish trial gave 195 people who had just lost weight a year of supervised exercise, a GLP-1 medicine (liraglutide), both, or neither. Then all treatment stopped, and 109 of them were weighed again a year later.13

  • Medicine plus exercise, against the medicine alone: about 2.5 kg less regain. That difference was small enough that it could have been chance.13
  • Exercise alone, against the medicine alone: the medicine-only group regained about 6 kg more.13

So exercise during treatment looks helpful, but this one small trial can't prove how much it adds once you stop the medicine.

Some evidenceKeep exercisingStarted while on the medicine, and kept going after. Helpful, but tested in only one small trial.13
RecommendedBehavioural supportWHO advises structured help with eating and habits alongside GLP-1s.11
PromisingA lower doseTested for tirzepatide only, in one trial.3
UnprovenSlow tapering to zeroNo finished randomised trial yet.12

That exercise trial used liraglutide, an older daily GLP-1, and followed 109 people.13 Protein and strength training to protect muscle are covered in Guide 8: Life on a GLP-1.

What does staying on it cost over years?

If you need it long term, the cost is long term too. At the official prices on Abu Dhabi's drug list from 2 October 2026, 5 years of the medicine alone costs from about AED 74,500 to about AED 112,700, depending on the medicine and dose.

These are examples, not a price list. A pen holds 4 weekly doses, so a year is 13 pens. Medicine prices in the UAE are fixed nationally, so the pharmacy doesn't change the price:14,15

Mounjaro (tirzepatide), any dose14
Per 4 weeksAED 1,734
1 yearAED 22,542
3 yearsAED 67,626
5 yearsAED 112,710
Wegovy (semaglutide) 2.4 mg pen14
Per 4 weeksAED 1,712
1 yearAED 22,256
3 yearsAED 66,768
5 yearsAED 111,280
Wegovy (semaglutide) 1 mg pen, a lower dose14
Per 4 weeksAED 1,145.50
1 yearAED 14,892
3 yearsAED 44,675
5 yearsAED 74,458

Medicine only. Doctor visits, blood tests, needles and any programme fees are extra.

How we worked out these prices

Prices are the official prices to the public on Abu Dhabi's drug list, in force from 2 Oct 2026 and checked 12 Oct 2026.14 Our arithmetic: price × 13 pens a year (52 weekly doses), × 39 for 3 years and × 65 for 5 years. Mounjaro costs the same at every strength, so its total doesn't depend on your dose. Prices may be revised by the authorities; we re-check them every quarter.

In one Danish GP practice, 38% had stopped semaglutide within a year, for all reasons.12 Before you start, ask whether you could afford it for years, not months: most insurance plans don't pay for these medicines for weight.16,17 Guide 6 covers official prices and insurance in the UAE.

When is stopping the right call?

Stopping is a reasonable choice in several situations. A medicine that harms you, isn't working, or can't be paid for is not worth staying on. These are the common reasons.

  • Side effects you can't live with, or a serious one such as pancreatitis. Guide 5 lists the warning signs.
  • Planning a pregnancy. The Wegovy label says stop semaglutide at least 2 months before trying, because it stays in the body a long time.4 It also says stop if you become pregnant.4 The tirzepatide label warns it may harm an unborn baby.18
  • An operation or sedation. These medicines slow the stomach. Rarely, people have breathed in stomach contents during anaesthesia.4 The labels say to tell your surgeon you take one. They say there isn't enough data to know if pausing it helps.4,18
  • It isn't working. Abu Dhabi's obesity standard says to continue beyond 6 months only if you've lost at least 5% of your starting weight.19 In the Thiqa programme, cover stops for people who don't meet its weight-loss and activity targets.20
  • Cost, if paying for it is straining your family.
  • It was never the right medicine for you, for example taken for a few kilos before an event, or without a proper prescription. See Guide 4.

How do you stop safely?

With your doctor, and with a plan for what comes next. Your weight, blood sugar and blood pressure will need watching for months.

1Talk to the doctor who prescribed it
2Agree a plan: stop, lower dose, or pause
3If diabetic: a replacement plan for sugar control
4Check weight, sugar and blood pressure in the months after

Our summary of the evidence on this page, not a clinical protocol.

If you have diabetes, stopping can push your HbA1c up.9 Your doctor may need to add or change another sugar medicine. Don't just stop and wait to see.

Keep the habits you built: regular exercise and the eating patterns that worked. They give you the best chance of holding on to some of the loss.13

What if you miss doses or can't get supply?

A short gap is usually fine. After a longer gap, the label advice is to restart at a lower dose and build up again.

Semaglutide (Wegovy label): take a missed dose within 5 days of the missed dose, that is, as long as your next dose is more than 2 days away. After that, skip it and take the next one on your usual day. If you've missed 2 or more weekly doses in a row, the label restarts you at a lower dose.4

Tirzepatide (Mounjaro label): take a missed dose within 4 days of the missed dose. After that, skip it and take the next one on your usual day.18 The label gives no rule for restarting after a long gap. Ask your doctor what dose to restart on.

Don't restart at your old full dose after a long break without asking your doctor. The label restarts low to cut the risk of stomach side effects.4 Restarting counts as starting again, so the pill advice applies too: the tirzepatide label says it may make the contraceptive pill work less well, and to use a barrier method, such as condoms, for 4 weeks after starting and after each dose increase.18
UAE note: if your pharmacy is out of stock, ask your doctor before switching to another medicine or dose. Don't fill a gap from social media or an unknown website: fake Ozempic and Mounjaro have been sold that way in the UAE.21,22

Questions people ask

Will all the weight come back if I stop?

Not always all of it. In the main semaglutide trial (STEP 1), people regained about two-thirds of the lost weight in the year after stopping, and ended 5.6% below their starting weight on average.1 Results vary a lot between people.8

Can I stop and start again later?

Many people do, but plan it with your doctor. After 2 or more missed weekly doses, the Wegovy label says to restart at a lower dose and build up again.4

Is it safe to just stop suddenly?

In the trials, people stopped all at once. What followed was a slow return of weight, blood sugar and blood pressure.1,2 If you have diabetes, you need a sugar plan first.

Can I take a lower dose instead of stopping?

For tirzepatide, one trial (SURMOUNT-MAINTAIN) found a 5 mg dose kept most of the loss, though less than the full dose.3 For semaglutide, there's no finished trial yet.12

How long before pregnancy should I stop?

At least 2 months for semaglutide, says the Wegovy label.4 The tirzepatide label gives no set gap, so plan this with your doctor.18

Before you move on

  • Most people regain much of the weight within a year of stopping.
  • Blood sugar and blood pressure tend to rise again too.
  • A lower dose is tested for tirzepatide only; tapering is unproven.
  • Keeping up exercise and good habits gives you the best chance of holding on to some of the loss.
  • Long-term use can cost over AED 100,000 over 5 years.
  • Stop with your doctor; if diabetic, have a sugar plan first.
All 9 guides done

You've finished the 9 guides

Pick the path that fits you. Each one points to the parts that matter most for your situation.

Back to the homepage →
Was this guide easy to understand?

Sources

  1. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022;24(8):1553–64. doi:10.1111/dom.14725
  2. West S et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ, 7 January 2026. doi:10.1136/bmj-2025-085304
  3. Horn DB et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). The Lancet, 2026. doi:10.1016/S0140-6736(26)00656-2. Funded by Eli Lilly.
  4. Novo Nordisk. Wegovy (semaglutide) US prescribing information, revised June 2026: sections 2.4 (missed doses), 5.10 (anaesthesia), 8.3 (pregnancy planning), 12.3 (half-life). PDF
  5. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA, 2021;325(14):1414–25. doi:10.1001/jama.2021.3224
  6. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA, 2024;331(1):38–48. doi:10.1001/jama.2023.24945
  7. Budini B et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine, 2026;93:103796. doi:10.1016/j.eclinm.2026.103796
  8. Horn DB et al. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal: a post hoc analysis of SURMOUNT-4. JAMA Internal Medicine, 2026;186(2):157–67. doi:10.1001/jamainternmed.2025.6112
  9. Tzang CC et al. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. eClinicalMedicine, 2025. doi:10.1016/j.eclinm.2025.103680
  10. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. NEJM, 2011;365:1597–604. doi:10.1056/NEJMoa1105816 (a diet study, not a GLP-1 study)
  11. Celletti F, Farrar J, De Regil L. World Health Organization guideline on the use and indications of GLP-1 therapies for the treatment of obesity in adults (December 2025). JAMA, 2026. doi:10.1001/jama.2025.24288
  12. Skandov MD et al. Real-world use of semaglutide for weight management: dose titration, discontinuation patterns and weight changes. Diabetes, Obesity and Metabolism, 2026. doi:10.1111/dom.71092; and ClinicalTrials.gov NCT07783854 (semaglutide dose-tapering trial, not yet recruiting, checked 5 Oct 2026).
  13. Jensen SBK et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment. eClinicalMedicine, 2024;69:102475. doi:10.1016/j.eclinm.2024.102475
  14. Department of Health – Abu Dhabi. Shafafiya drug price list (Drugs.xlsx), released 26 September 2026, effective 2 October 2026: official "Package Price to Public" for each pack named here, each listed as a prescription-only medicine ("POM"). Downloaded and checked 12 October 2026. shafafiyaportal.doh.gov.ae (XLSX)
  15. Mondaq (law firm analysis). Pricing of pharmaceutical products in the United Arab Emirates (prices fixed at registration by a Ministry committee, with "fixed margins for the distributors and pharmacies"). 29 September 2016; older than the 2025 medicines law. mondaq.com
  16. Cigna. Essential Benefits Plan (Dubai Health Authority basic plan), table of benefits: medicines "As per DHA formulary", maximum AED 2,500 a year with 30% co-insurance; exclusions 8 ("Surgical and non-surgical treatment for obesity (including morbid obesity), and any other weight control programs, services, or supplies") and 9 ("pharmacological weight reduction regimens"). Checked 12 October 2026. PDF
  17. Gulf News. Anti-obesity drugs Ozempic, Wegovy, Mounjaro: are they getting cheaper? (Ozempic lower-dose pens "around Dh740"; Mounjaro pens "often above Dh1,700"; GLP-1s "remain largely out-of-pocket expenses, with limited insurance coverage typically restricted to diabetes or specific metabolic conditions"). 7 February 2026. gulfnews.com
  18. Eli Lilly. Mounjaro (tirzepatide) US prescribing information, revised August 2026: missed doses, 5.9 (anaesthesia), 8.1 and 8.3 (pregnancy, oral contraceptives). PDF
  19. Department of Health – Abu Dhabi. Standard for Non-Surgical Management of Obesity, DOH/ST/HPS/Non-Surgical-MO/V1/2025, February 2025 (GLP-1 starting criteria: BMI 30 or more with a weight-related comorbidity, or over 40; "The obesity certified physician determines the initiation time of pharmacological treatment"; continue beyond 6 months only with at least 5% weight loss; Asian origin and BMI over 23). Checked 12 October 2026. doh.gov.ae
  20. Department of Health – Abu Dhabi. Thiqa reimbursement policy for obesity medications, DoH/Policy/TRP-OMM/HPS/V1/2025, effective 11 June 2025 (adults 18+; BMI bands and listed complications; certified prescribers; more than 5% weight loss plus "75 min vigorous exercise per week", "150 min moderate exercise per week" or "10,000 steps per day on average", tracked through the Sahatna app; 1-month trial, up to 3 months' supply at a time, review at 4 months). Checked 12 October 2026. doh.gov.ae
  21. Department of Health – Abu Dhabi. Circular 10/2025, 4 February 2025, "Alert Against the Use of Counterfeit Version of Ozempic and Mounjaro" sold through social media; the public should not buy them without a prescription, online or through adverts. Summarised, not reproduced. doh.gov.ae
  22. Department of Health – Abu Dhabi. Circular 208/2024, 25 October 2024, relaying a Ministry of Health and Prevention alert on a counterfeit Mounjaro 15 mg/0.5 ml single-dose pen pack, labelled in English and Arabic (the Ministry's lab could not identify tirzepatide). Summarised, not reproduced. doh.gov.ae

Last checked 12 Oct 2026 · Next review due Jan 2027 · Report an error

How this guide was made. Written by the GLP Guidebook team from the sources above: published trials, drug labels, UAE health-authority and insurance documents, official prices and named news reports. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. In a medical emergency, call 998 for an ambulance, or 999. How we write